← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Envisagenics, Inc.
Long Island City, NY
$4,226,929
Total funding
4
Grants
Funding over time
peak $1.1M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,226,929 · 4
By mechanism
R44$3,700,427 · 2
R43$526,502 · 2
Investigators at Envisagenics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$1,018,170
R44 · FY2022 · CA
SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$982,774
R44 · FY2018 · GM
Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$980,257
R44 · FY2023 · CA
SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$517,226
R44 · FY2019 · GM
A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data$301,502
R43 · FY2019 · CA
SpliceCore: A cloud-based platform to detect, quantify and interpret alternative splicing variation from next-generation sequencing data.$225,000
R43 · FY2015 · GM
SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$125,000
R44 · FY2018 · GM
Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$77,000
R44 · FY2023 · CA